Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Pantheon International director raises stake

(Sharecast News) - Pantheon International revealed on Thursday that non-executive director John Burgess had acquired 166,038 ordinary shares in the FTSE 250-listed investment trust. Burgess, who made the purchase via his interest in The November 1990 Trust, snapped up the shares at an average price of 324.65p each, for a total value of £539,047.48.

As of 1620 BST, Pantheon shares were flat at 323.50p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Pantheon International (PIN) Director name: Burgess ,John Amount purchased: 166,038 @ 324.65p Value: £539,047.48

Staffline Group (STAF) Director name: Spain,Thomas Amount purchased: 101,266 @ 35.55p Value: £36,000.06

Hydrogen Utopia International (HUI) Director name: White,Howard Amount purchased: 500,000 @ 4.88p Value: £24,400.00

Seed Innovations Limited (SEED) Director name: Jersey,Lance De Amount purchased: 1,000,000 @ 1.45p Value: £14,500.00

Top Director Sells

Bloomsbury Publishing (BMY) Director name: Newton,Nigel Amount sold: 58,378 @ 713.30p Value: £416,410.27

Bloomsbury Publishing (BMY) Director name: Scott-Bayfield,Penny Amount sold: 38,085 @ 713.30p Value: £271,660.30

Staffline Group (STAF) Director name: Spain,Thomas Amount sold: 101,266 @ 35.55p Value: £36,000.06

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 600 @ $4.30 Value: $2,127.48

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 400 @ $4.26 Value: $1,403.48

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 400 @ $4.23 Value: $1,395.23

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 301 @ $4.27 Value: $1,059.84

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 296 @ $4.31 Value: $1,052.00

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 300 @ $4.23 Value: $1,046.43

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 206 @ $4.23 Value: $718.55

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 200 @ $4.35 Value: $717.41

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 152 @ $4.28 Value: $536.46

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 87 @ $4.29 Value: $307.77

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 58 @ $4.26 Value: $203.98

Share this article

Related Sharecast Articles

Director dealings: CVS Group's Scott Morrison snaps up shares
(Sharecast News) - CVS Group revealed on Thursday that group general counsel Scott Morrison had acquired 987 ordinary shares in the FTSE 250-listed veterinary services business.
Director dealings: Convatec CEO snaps up shares
(Sharecast News) - Convatec revealed on Wednesday that chief executive Jonny Mason had acquired 50,000 ordinary shares in the FTSE 100-listed medical products and technologies firm.
Director dealings: Experian director snaps up shares
(Sharecast News) - Experian revealed on Tuesday that non-executive director Eduardo Vassimon snapped up 5,650 ordinary shares in the FTSE 100-listed data and technology firm.
Director dealings: 3i Group CEO invests, Shell boss makes EUR 1.49m sale
(Sharecast News) - Among the director dealings disclosed to the market in London on Friday, 3i Group chief executive Simon Borrows bought shares in the investment company, while Shell chief executive Wael Sawan sold shares in the energy major.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.